INDIVIOR PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.53 USD | +1.47% |
|
+1.10% | +8.25% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.27B 99.99B | Sales 2025 * | 1.42B 112B | Capitalization | 2.24B 177B |
|---|---|---|---|---|---|
| Net income 2024 * | 268M 21.13B | Net income 2025 * | 341M 26.89B | EV / Sales 2024 * | 1.54 x |
| Net cash position 2024 * | 287M 22.63B | Net cash position 2025 * | 587M 46.28B | EV / Sales 2025 * | 1.16 x |
| P/E ratio 2024 * |
8.99
x | P/E ratio 2025 * |
6.9
x | Employees | 1,000 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.69% |
More Fundamentals
* Assessed data
More news
Latest transcript on Indivior PLC
More recommendations
More press releases
| 1 day | +1.47% | ||
| 1 week | +1.10% | ||
| Current month | -9.77% | ||
| 1 month | -5.70% | ||
| 3 months | -20.34% | ||
| 6 months | +0.85% | ||
| Current year | +8.25% |
1 week
16.10
17.09
1 month
16.1018.59
Current year
15.0023.22
1 year
14.3824.90
3 years
9.9026.50
5 years
2.1326.50
10 years
1.7533.60
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Crossley
CEO | Chief Executive Officer | - | 31/12/11 |
Ryan Preblick
DFI | Director of Finance/CFO | - | 31/12/11 |
Cynthia Cetani
CMP | Compliance Officer | - | 30/09/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 31/10/19 | |
Barbara Ryan
BRD | Director/Board Member | 64 | 31/05/22 |
Mark Stejbach
BRD | Director/Board Member | 61 | 23/03/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/06/24 | 16.53 | +1.47% | 48,997 |
| 13/06/24 | 16.29 | -3.32% | 55,273 |
| 12/06/24 | 16.85 | -0.12% | 31,936 |
| 11/06/24 | 16.87 | -0.59% | 41,208 |
| 10/06/24 | 16.97 | +3.79% | 60,892 |
Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm
More quotes
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
Sector
Pharmaceuticals
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.71
USD
Average target price
30.86
USD
Spread / Average Target
+84.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.36% | 79.99B | |
| +15.93% | 9.25B | |
| +42.06% | 4.45B | |
| -22.01% | 4.43B | |
| +8.28% | 4.03B | |
| -26.61% | 2.18B | |
| +11.64% | 2.02B | |
| -42.69% | 1.79B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- INDV Stock
- INDV Stock
